OCUP - The Buzz Show: Ocuphire Pharma Inc. (NASDAQ: OCUP) First Patients in the MIRA-3 Phase 3 Trial

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Ocuphire Pharma, Inc. Announces Enrollment of First Patients in the MIRA-3 Phase 3 pivotal trial”

Ocuphire Pharma, Inc. (NASDAQ: OCUP) surged over 44% in premarket trading after the company announced that the first subjects have been enrolled in the MIRA-3 Phase 3 pivotal trial.

With 6 sites enrolling subjects within days of activation and 10 more sites expected to start screening shortly, top-line results from the MIRA-3 trial evaluating Nyxol® Eye Drops are expected in early 2022 .

Ocuphire is a publicly-traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications.

For more information, please visit: Ocuphire Pharma, Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post “The Buzz” Show: Ocuphire Pharma, Inc. (NASDAQ: OCUP) First Patients in the MIRA-3 Phase 3 Trial first appeared on Financial Buzz .

For further details see: